Nuvectra Corp Company Profile (NASDAQ:NVTR)

Nuvectra Corp trades on the NASDAQ under the ticker symbol "NVTR."

Nuvectra Corp (NASDAQ:NVTR) released its quarterly earnings data on Tuesday, May, 9th. The company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.25) by $0.02. The firm earned $5 million during the quarter, compared to analysts' expectations of $4.61 million. Nuvectra Corp had a negative net margin of 320.73% and a negative return on equity of 33.89%. The business's revenue for the quarter was up 47.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.70) earnings per share. View Nuvectra Corp's Earnings History.

3 brokers have issued 12 month price objectives for Nuvectra Corp's shares. Their forecasts range from $10.00 to $14.00. On average, they anticipate Nuvectra Corp's share price to reach $12.00 in the next twelve months. View Analyst Ratings for Nuvectra Corp.

Nuvectra Corp saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 68,088 shares, an increase of 2.4% from the April 13th total of 66,517 shares. Based on an average daily volume of 75,365 shares, the days-to-cover ratio is presently 0.9 days.

Some companies that are related to Nuvectra Corp include Abeona Therapeutics (ABEO), Ardelyx (ARDX), Corindus Vascular Robotics (CVRS), BioScrip (BIOS), Chimerix (CMRX), Corium International (CORI), Cascadian Therapeutics (CASC), Immune Design Corp (IMDZ), Cempra (CEMP), Fortress Biotech (FBIO), Stemline Therapeutics (STML), Viralytics Ltd Spon (VRACY), Osiris Therapeutics (OSIR), Oxford Biomedica (OXBDF), Enzymotec Ltd (ENZY), Madrigal Pharmaceuticals (MDGL), Pieris Pharmaceuticals (PIRS) and Neos Therapeutics (NEOS).

Nuvectra Corp's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (8.20%), Dimensional Fund Advisors LP (6.59%), Vanguard Group Inc. (2.83%), Hodges Capital Management Inc. (1.86%), Essex Investment Management Co. LLC (1.38%) and Wells Fargo & Company MN (1.09%). Company insiders that own Nuvectra Corp stock include David D Johnson, Joseph A Miller, Scott F Drees and Thomas Kelley Hickman. View Institutional Ownership Trends for Nuvectra Corp.

Nuvectra Corp's stock was sold by a variety of institutional investors in the last quarter, including Tudor Investment Corp ET AL, Goldman Sachs Group Inc., Sessa Capital IM L.P., Renaissance Technologies LLC, Dimensional Fund Advisors LP and California Public Employees Retirement System. View Insider Buying and Selling for Nuvectra Corp.

Nuvectra Corp's stock was bought by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Gilder Gagnon Howe & Co. LLC, Essex Investment Management Co. LLC, Hodges Capital Management Inc., FNY Partners Fund LP, Vanguard Group Inc., Wells Fargo & Company MN and Stifel Financial Corp. Company insiders that have bought Nuvectra Corp stock in the last two years include David D Johnson, Joseph A Miller and Scott F Drees. View Insider Buying and Selling for Nuvectra Corp.

Shares of Nuvectra Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Nuvectra Corp stock can currently be purchased for approximately $10.81.